NEW YORK – Hematology and clinical chemistry firm Horiba announced on Tuesday that it has acquired MedTest Holdings, which includes MedTest Dx, Pointe Scientific, Clinitox Diagnostix, and Medical Laboratory Solutions.
Kyoto, Japan-based Horiba said the acquisition will combine the technology of its Horiba Medical segment with MedTest Dx technology, Clinitox and Pointe Scientific's research and development and manufacturing capabilities, and the expertise of MedTest's subsidiaries in 510(k) and CLIA clearances.
Financial and other terms of the deal were not disclosed.
"This acquisition provides Horiba Medical the opportunity to address the IVD market's multidisciplinary requirements along with the complimentary innovative technology of Pointe Scientific and MedTest's high quality Chemistry solutions," Jai Hakhu, chairman and CEO of Horiba Instruments, said in a statement.
In December, Horiba Medical received clearances from the US Food and Drug Administration and Health Canada for its Yumizen C1200 clinical chemistry analyzer.
Horiba Medical offers a variety of hematology, hemostasis, and clinical chemistry products, including analyzers, reagents, and consumables, for use with in vitro diagnostics. Canton, Michigan-based MedTest Holdings provides screening instruments, reagent manufacturing, and liquid chromatography-mass spectrometry toxicology confirmation products for clinical chemistry, drugs of abuse, and toxicology testing.